Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
64 hedge funds and large institutions have $82.5M invested in Oncternal Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
100% more capital invested
Capital invested by funds: $41.2M → $82.5M (+$41.2M)
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
23% more funds holding
Funds holding: 52 → 64 (+12)
51% less call options, than puts
Call options by funds: $1.41M | Put options by funds: $2.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.33M |
| 2 |
BlackRock
New York
|
+$4.84M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.14M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.88M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.77M |
| 2 |
6CM
683 Capital Management
New York
|
-$3.57M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.78M |
| 4 |
EP
Eversept Partners
New York
|
-$1.69M |
| 5 |
ACM
Altium Capital Management
New York
|
-$1.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Tudor Investment Corp
Stamford,
Connecticut
| – | -$63K | -640 | Closed |
|
|
GIA
77
Gladstone Institutional Advisory
Palm Beach Gardens,
Florida
| – | -$50K | -508 | Closed |
|
|
PFO
78
Pathstone Family Office
Englewood,
New Jersey
| – | -$12K | -121 | Closed |
|
ONCT Hedge Fund Activity: Q1 2021 in Review
64 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2021, worth a combined $82.5M — up 100% from $41.2M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ONCT positions and 14 closed out — a net gain of 15 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $6.33M. The largest seller was Ikarian Capital, cutting an estimated $3.77M.
- 64 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2021, up from 52 in Q4 2020.
- Funds reported $82.5M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2021, up 100% quarter-over-quarter.
- 29 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +15 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2021 was Invesco, an estimated $6.33M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2021 was Ikarian Capital, an estimated $3.77M sold.
Based on aggregated 13F filings for Q1 2021.